# Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

> **NCT01465802** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 236 (actual)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Dacomitinib
- **DRUG:** Dacomitinib
- **DRUG:** Doxycycline
- **DRUG:** Probiotic
- **DRUG:** Alclometasone cream

## Key facts

- **NCT ID:** NCT01465802
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-26
- **Primary completion:** 2015-05-18
- **Final completion:** 2015-05-18
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465802, "Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01465802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*